Proteasome Inhibitors

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61989592%3A15310%2F12%3A33141663" target="_blank" >RIV/61989592:15310/12:33141663 - isvavai.cz</a>

Výsledek na webu

<a href="http://www.sciencedirect.com/science/article/pii/B9780123978639000055" target="_blank" >http://www.sciencedirect.com/science/article/pii/B9780123978639000055</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1016/B978-0-12-397863-9.00005-5" target="_blank" >10.1016/B978-0-12-397863-9.00005-5</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Proteasome Inhibitors

Popis výsledku v původním jazyce

In May 2003, the US Food and Drug Administration (FDA) granted accelerated approval for the use of the first-in-class proteasome inhibitor bortezomib as a third-line therapy in multiple myeloma, and the European Union followed suit a year later. Bortezomib has subsequently been approved for multiple myeloma as a second-line treatment on its own and as a first-line therapy in combination with an alkylating agent and a corticosteroid. Furthermore, bortezomib has also been approved as a second-line therapyfor mantle cell lymphoma. In this chapter, the focus is on the current clinical research on bortezomib, its adverse effects, and the resistance of multiple myeloma patients to bortezomib-based therapy. The various applications of bortezomib in differentdiseases and recent advances in the development of a new generation of inhibitors that target the proteasome or other parts of the ubiquitin-proteasome system are also reviewed.

Název v anglickém jazyce

Proteasome Inhibitors

Popis výsledku anglicky

In May 2003, the US Food and Drug Administration (FDA) granted accelerated approval for the use of the first-in-class proteasome inhibitor bortezomib as a third-line therapy in multiple myeloma, and the European Union followed suit a year later. Bortezomib has subsequently been approved for multiple myeloma as a second-line treatment on its own and as a first-line therapy in combination with an alkylating agent and a corticosteroid. Furthermore, bortezomib has also been approved as a second-line therapyfor mantle cell lymphoma. In this chapter, the focus is on the current clinical research on bortezomib, its adverse effects, and the resistance of multiple myeloma patients to bortezomib-based therapy. The various applications of bortezomib in differentdiseases and recent advances in the development of a new generation of inhibitors that target the proteasome or other parts of the ubiquitin-proteasome system are also reviewed.

Druh

C - Kapitola v odborné knize

CEP obor

FR - Farmakologie a lékárnická chemie

OECD FORD obor

—

Projekt

<a href="/cs/project/EE.2.3.20.0062" target="_blank" >EE.2.3.20.0062: Levný lék antabus jako protinádorové léčivo: mechanismus účinku a klinické testy</a><br>

Návaznosti

P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)

Rok uplatnění

2012

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název knihy nebo sborníku

The Proteasomal System in Aging and Disease

ISBN

978-0-12-397863-9

Počet stran výsledku

66

Strana od-do

161-226

Počet stran knihy

465

Název nakladatele

Elsevier Academic Press

Místo vydání

San Diego

Kód UT WoS kapitoly

—